Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David F Gebhard

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
European Journal of Gastroenterology & Hepatology|February 9, 2012
Antitumor effect of vascular endothelial growth factor inhibitor sunitinib in preclinical models of hepatocellular carcinomaCedo Martin Bagi, David F Gebhard, Catharine J Andresen
Current Protocols in Toxicology|May 10, 2011
High-throughput assays for assessing mitochondrial dysfunction caused by compounds that impair mtDNA-encoded protein levels in eukaryotic cellsSashi Nadanaciva, James Murray, Casey Wilson, et al.
Journal of Biomolecular Screening|July 14, 2010
High-content screening for compounds that affect mtDNA-encoded protein levels in eukaryotic cellsSashi Nadanaciva, Keith Dillman, David F Gebhard, et al.
Toxicology in Vitro : an International Journal Published in Association with BIBRA|December 28, 2010
A high content screening assay for identifying lysosomotropic compoundsSashi Nadanaciva, Shuyan Lu, David F Gebhard, et al.
Journal of Pharmaceutical Sciences|July 19, 2011
Development of a new permeability assay using low-efflux MDCKII cellsLi Di, Carrie Whitney-Pickett, John P Umland, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 1, 2007
Proline-rich tyrosine kinase 2 regulates osteoprogenitor cells and bone formation, and offers an anabolic treatment approach for osteoporosisLeonard Buckbinder, David T Crawford, Hong Qi, et al.
Mabs|September 26, 2012
Biochemical and pharmacological characterization of human c-Met neutralizing monoclonal antibody CE-355621Neil R Michaud, Jitesh P Jani, Stephen Hillerman, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
European Journal of Gastroenterology & Hepatology|February 9, 2012
Antitumor effect of vascular endothelial growth factor inhibitor sunitinib in preclinical models of hepatocellular carcinomaCedo Martin Bagi, David F Gebhard, Catharine J Andresen
Current Protocols in Toxicology|May 10, 2011
High-throughput assays for assessing mitochondrial dysfunction caused by compounds that impair mtDNA-encoded protein levels in eukaryotic cellsSashi Nadanaciva, James Murray, Casey Wilson, et al.
Journal of Biomolecular Screening|July 14, 2010
High-content screening for compounds that affect mtDNA-encoded protein levels in eukaryotic cellsSashi Nadanaciva, Keith Dillman, David F Gebhard, et al.
Toxicology in Vitro : an International Journal Published in Association with BIBRA|December 28, 2010
A high content screening assay for identifying lysosomotropic compoundsSashi Nadanaciva, Shuyan Lu, David F Gebhard, et al.
Journal of Pharmaceutical Sciences|July 19, 2011
Development of a new permeability assay using low-efflux MDCKII cellsLi Di, Carrie Whitney-Pickett, John P Umland, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 1, 2007
Proline-rich tyrosine kinase 2 regulates osteoprogenitor cells and bone formation, and offers an anabolic treatment approach for osteoporosisLeonard Buckbinder, David T Crawford, Hong Qi, et al.
Mabs|September 26, 2012
Biochemical and pharmacological characterization of human c-Met neutralizing monoclonal antibody CE-355621Neil R Michaud, Jitesh P Jani, Stephen Hillerman, et al.
Pageof 1